Tuesday, November 17, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Press releaseGlobeNewswire· July 7, 2026

ARS Pharmaceuticals Announces CEO Succession

View original at globenewswire.com
ARS Pharmaceuticals Announces CEO Succession Richard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of Leadership Since Co-Founding the Company Donn Casale, President, Appointed Chief Executive Officer and Director SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc…
Opening lines of the source · GlobeNewswire · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Rich was integral to guiding ARS Pharma from development to establishing neffy as a leading treatment for adults and children with Type 1 allergic reactions, and Donn Casale has the right background and experience to drive the company through its next phase, growing the neffy franchise and positioning ARS Pharma for value creation.

    60% confidence
  • Donn Casale expressed excitement about leading ARS Pharma's next evolution and confidence in growing neffy's impact.

    60% confidence

Cited in these Via News reports